Group 1 - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - The board of directors approved the relevant proposals on January 22, 2026, and the company will consider the interests of existing shareholders during the issuance process [1] - The specific details regarding the issuance and listing are yet to be finalized, and there is significant uncertainty regarding the approval and implementation of the plan [1] Group 2 - The company is establishing an overseas headquarters for intelligent manufacturing in the West Coast New Area, with a total land area of 55,403 square meters (approximately 83.1 acres) [3]

每经AI快讯，1月23日，特锐德（300001）公告，公司于2026年1月22日召开第六届董事会第八次会 议，审议通过拟发行H股股票并在香港联交所主板挂牌上市的议案。此举旨在推进全球化战略布局，加 快海外业务发展。本次发行上市尚需提交公司股东会审议，还需取得相关政府机构、监管机构、证券交 易所的备案、批准或核准。目前具体细节未最终确定，能否实施有重大不确定性。 ...

Core Viewpoint - The company, Teruid (300001.SZ), aims to enhance its global strategy and accelerate overseas business development by issuing H-shares and applying for listing on the Hong Kong Stock Exchange [1] Group 1: Global Strategy and Business Development - The company plans to issue overseas listed foreign shares (H-shares) to support its globalization strategy [1] - The goal is to create an international capital operation platform and improve the company's international brand image and overall competitiveness [1] Group 2: Shareholder Considerations and Timing - The company will take into account the interests of existing shareholders and the conditions of domestic and foreign capital markets [1] - The issuance and listing will be completed at an appropriate time and issuance window within the validity period of the shareholders' meeting resolution, which is 24 months from the approval date or any extended period agreed upon [1]

格隆汇1月23日丨特锐德(300001.SZ)公布，为进一步推进公司全球化战略布局，加快海外业务发展，打 造国际化资本运作平台，提升国际品牌形象及综合竞争力，公司拟发行境外上市外资股（H股）股票并 申请于香港联合交易所有限公司（简称"香港联交所"）主板挂牌上市。公司将充分考虑现有股东的利益 和境内外资本市场的情况，在股东会决议有效期内（即经公司股东会审议通过之日起24个月或同意延长 的其他期限）选择适当的时机和发行窗口完成本次发行上市。 ...

Core Viewpoint - The company plans to issue overseas shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange to advance its global strategy and support high-quality development [1] Group 1 - The company aims to enhance its international capital operation platform [1] - The issuance will consider the interests of existing shareholders and the conditions of domestic and international capital markets [1] - The company intends to complete the issuance and listing at an opportune time within the validity period of the shareholders' meeting resolution [1]

Core Viewpoint - The company plans to issue H-shares and apply for listing on the main board of the Hong Kong Stock Exchange to advance its global strategy and enhance its international capital operations platform [1] Group 1 - The company will hold its sixth board meeting on January 21, 2026, to review and approve the proposal for issuing H-shares [1] - The issuance of H-shares is part of the company's strategy to support high-quality development [1] - The company aims to further its global strategic layout through this initiative [1]

Group 1 - The company, Xinlitai (002294), announced plans to issue overseas shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange to further advance its global strategic layout [1] - The initiative aims to create an international capital operation platform to support the company's high-quality development [1]

Core Viewpoint - The company has achieved large-scale production at its Vietnam factory, enhancing its vertical integration in manufacturing, which supports performance growth [1] Group 1: Manufacturing Capabilities - The Vietnam factory has complete vertical integration capabilities from SMT, injection molding to assembly [1] - The company is actively advancing its expansion project for computer peripheral products in Vietnam [1] Group 2: Competitive Advantages - The combination of a mature local electronics supply chain and the company's intelligent manufacturing system provides a comprehensive advantage in cost control [1] - Overall profitability and market competitiveness are continuously improving, making the Vietnam facility a crucial part of the company's global strategic layout [1]

Core Viewpoint - Xianle Health's H-share listing aims to deepen the company's global strategy, leveraging international capital market advantages to accelerate overseas business development [1][3]. Group 1: Company Overview - Xianle Health, established in 1993 and headquartered in Shantou, Guangdong, is one of China's large CDMO (Contract Development and Manufacturing Organization) companies in the nutrition and health food sector [3]. - The company was listed on the Shenzhen Stock Exchange's ChiNext board on September 25, 2019, becoming the first A-share CDMO company in the nutrition and health food industry in China [3]. - If the Hong Kong listing is successful, Xianle Health is expected to become the first A+H listed company in the nutrition and health sector [3]. Group 2: Globalization Strategy - Xianle Health has been pursuing a globalization strategy for years, establishing localized supply capabilities in China (Shantou, Ma'anshan, Zhuhai), the United States, and Germany through investments and acquisitions [3]. - The company established a presence in the U.S. as early as 2012 and acquired Sirio Germany in 2016 to enhance its European capabilities [3]. - In January 2023, Xianle Health acquired control of U.S.-based BFPC, a leading CDMO in nutritional supplements, to strengthen its production base across North America and Europe [4]. Group 3: Financial Performance - For the first three quarters of 2025, Xianle Health reported total revenue of 3.291 billion yuan, a year-on-year increase of 7.96%, and a net profit attributable to shareholders of 260 million yuan, up 8.53% [9][10]. - The company’s operating cash flow for the reporting period was 411 million yuan, reflecting a 45.50% increase [10]. - As of June 30, 2025, the company’s total assets were approximately 5.878 billion yuan, with equity attributable to shareholders at about 2.654 billion yuan, marking a 22% increase from the previous year [10]. Group 4: Challenges and Risks - Despite the strategic acquisitions, BFPC has not contributed positively to Xianle Health's earnings, with losses reported for 2023 to the first half of 2025 totaling approximately 143 million yuan, 151 million yuan, and 86.94 million yuan respectively [4]. - The company has signed a non-binding letter of intent with a potential buyer for the acquisition of BFPC, indicating potential impairment risks related to the personal care business assets [7]. - As of June 30, 2025, the goodwill from the acquisition of BFPC was valued at 251 million yuan, representing 17.05% of the company's equity [7].

Group 1 - The stock of Feilong Co., Ltd. (002536) closed at 28.41 yuan on January 20, 2026, down 4.76% from the previous trading day, with a total market value of 16.33 billion yuan [1] - The stock opened at 29.55 yuan, reached a high of 29.9 yuan, and a low of 28.05 yuan, with a trading volume of 1.111 billion yuan and a turnover rate of 7.1% [1] - The company announced an increase in investment of no more than 300 million yuan in its wholly-owned subsidiary, Feilong International, which was approved on October 20, 2025 [1] Group 2 - The company has completed an initial capital increase of 100 million yuan for Feilong International and has finalized the business registration changes [1] - Following the capital increase, Feilong International's registered capital is now 1 million Singapore dollars and 695 million yuan, totaling approximately 700 million yuan [1] - The capital increase is primarily intended for investment in Longtai Auto Parts (Thailand) Co., Ltd., aligning with the company's globalization strategy and facilitating overseas market expansion, with no significant impact on the company's current financial status and operating results [1]